Published online May 7, 2024. doi: 10.3748/wjg.v30.i17.2321
Revised: March 25, 2024
Accepted: April 9, 2024
Published online: May 7, 2024
Processing time: 76 Days and 2.2 Hours
The advent of cutting-edge systemic therapies has driven advances in the treatment of hepatocellular carcinoma (HCC), and therapeutic strategies with multiple modes of delivery have been shown to be more efficacious than mono
To evaluate the clinical efficacy of targeted therapy plus immunotherapy combined with hepatic arterial infusion chemotherapy (HAIC) of FOLFOX in patients with unresectable HCC.
We enrolled 53 patients with unresectable HCC who received a combination of targeted therapy, immunotherapy, and HAIC of FOLFOX between December 2020 and June 2021 and assessed the efficacy and safety of the treatment regimen.
The objective response rate was 60.4% (32/53), complete response was 24.5% (13/53), partial response was 35.9% (19/53), and stable disease was 39.6% (21/53). The median duration of response and median progression-free survival were 9.1 and 13.9 months, respectively. The surgical conversion rate was 34.0% (18/53), and 1-year overall survival was 83.0% without critical complicating diseases or adverse events (AEs).
The regimen of HAIC of FOLFOX, targeted therapy, and immunotherapy was curative for patients with unresectable HCC, with no serious AEs and a high rate of surgical conversion.
Core Tip: The therapeutic strategy of combining multiple modes of drug delivery for the treatment of hepatocellular carcinoma (HCC) has been shown to be more efficacious than single treatment modality, but the underlying mechanism of action has not been clarified. In this study, we observed the clinical efficacy of targeted therapy plus immunotherapy combined with FOLFOX hepatic artery infusion chemotherapy in the treatment of unresectable HCC, which provides a clinical basis for the clinical application of the combination of therapy in HCC.